Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative

Amneal Pharmaceuticals (AMRX) has just posted its FY 2025 numbers, with Q4 revenue of US$814.3 million and basic EPS of US$0.11, capping a trailing twelve month run of US$3.0 billion in revenue and EPS of US$0.23. Over recent quarters the company has seen revenue move from US$702.5 million in Q3 2024 to US$730.5 million in Q4 2024, then to US$695.4 million, US$724.5 million, US$784.5 million and finally US$814.3 million through FY 2025, while quarterly EPS shifted from a loss of US$0.10 to US$0.04, US$0.07, US$0.01 and US$0.11 as profitability reset. With that backdrop and a trailing P/E of 60.3x alongside a return to profit, the latest results put the focus firmly on how durable Amneal’s margins really are.

See our full analysis for Amneal Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the main bullish and bearish narratives investors follow around Amneal today.

See what the community is saying about Amneal Pharmaceuticals

Profit Return Built on US$72.1m Trailing Net Income

• Over the last twelve months, Amneal generated US$72.1 million of net income on US$3.0 billion of revenue, after moving from a net loss of US$116.9 million a year earlier, so the business is now profitable on a trailing basis.
• Analysts’ consensus view sees this recent profitability as a starting point, with the company aiming to build on it through diversification into branded and complex products and a pipeline of 20 to 30 launches a year. The current US$3.0 billion revenue base and modest forecast 4.9% annual growth show that progress may be steadier than some of the more optimistic long term growth stories might suggest.

Revenue Growth Forecast At 4.9% Versus 10.3% Market

• Revenue is projected to grow at 4.9% per year compared with a 10.3% benchmark for the broader US market, pointing to slower expected top line expansion than the wider market even after reaching US$3.0 billion of trailing revenue.
• Bulls often highlight exposure to areas like biosimilars and complex injectables as potential drivers of higher growth. However, the 4.9% revenue forecast and heavy reliance on the US generics market mean the current numbers sit below that bullish ambition, while the consensus narrative still points to diversification and new category launches as key levers that could help earnings even if revenue growth runs behind the broader market.

🐂 Amneal Pharmaceuticals Bull Case

High 60.3x P/E With Interest Coverage Risk

• The shares trade on a trailing P/E of 60.3x versus 19.9x for the US pharmaceuticals industry and 24.3x for peers, while interest expense coverage is described as weak and trailing earnings include a US$35.2 million one off loss that affects reported earnings quality.
• Bears focus on that high multiple and the debt burden, and the data does give them material support, as the P/E is more than double peer levels and interest payments are not well covered by recent earnings. At the same time, the cited DCF fair value of US$67.44, compared with the current share price of US$13.83, means that anyone leaning on a cautious view has to reconcile those balance sheet and earnings quality concerns with a model that points to a large gap between price and estimated value.

🐻 Amneal Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Amneal Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Given the mix of positives and concerns in this earnings story, it makes sense to move quickly, review the details yourself, and then weigh 2 key rewards and 2 important warning signs as you form your own view.

See What Else Is Out There

Amneal’s high 60.3x P/E, modest 4.9% revenue growth forecast versus a 10.3% market benchmark, and weak interest coverage all point to elevated risk.

If that mix of slower projected growth and balance sheet pressure feels uncomfortable, use our 77 resilient stocks with low risk scores to quickly focus on companies with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com